Loading clinical trials...
Loading clinical trials...
Metabolic Causes of Thrombosis in Type 2 Diabetes Mellitus, Question 3
The purpose of this study is to learn more about why patients with diabetes have increased heart attacks, strokes and other illnesses due to blood clots causing blockage of a blood vessel. The proposed protocol will study the separate and combined effects of high glucose and high fats on certain cardiovascular responses in Type 2 DM.
Currently 75-80% of diabetes mellitus (DM) patients die due to thrombotic causes. Data from the Centers for Disease Control and Prevention released in 2000 indicated that mortality due to coronary artery disease is decreasing except in individuals with diabetes. Clearly the disordered metabolism, which includes abnormal metabolism of fats resulting in higher triglyceride and free fatty acid blood levels, occurring in diabetes predisposes these individuals to increased thrombotic events. Unless the underlying mechanisms responsible for these events can be identified, there will be an unprecedented number of diabetic patients suffering thrombotic episodes in the next 10 years. The specific aims of this study are to determine the effects of elevated free fatty acids and hyperglycemia (high glucose)on endothelial function and thrombolytic balance in patients with type 2 diabetes, and to determine the effects of increased insulin in this setting.
Age
18 - 60 years
Sex
ALL
Healthy Volunteers
Yes
Univerisity of Maryland, Baltimore
Baltimore, Maryland, United States
Start Date
July 1, 2009
Primary Completion Date
June 1, 2013
Completion Date
April 1, 2014
Last Updated
September 12, 2019
31
ACTUAL participants
euinsulinemic euglycemic glucose clamp
PROCEDURE
euinsulinemic hyperglycemic glucose clamp
PROCEDURE
Hyperinsulinemic euglycemic glucose clamp
PROCEDURE
Hyperinsulinemic hyperglycemic glucose clamp
PROCEDURE
Lead Sponsor
University of Maryland, Baltimore
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06671587